Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Ketamine for the Treatment of Depression in Parkinson's Disease (KET-PD)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04944017

Organisation Name: Yale University

Overal Status: Recruiting

Start Date: November 23, 2021

Last Update: August 26, 2022

Lead Sponsor: Yale University

Brief Summary: The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.

A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.

Conditions:
  • Parkinson's Disease
  • Depression


Total execution time in seconds: 0.30470681190491